JAK2 and essential thrombocythemia: The overall yield of NGS testing was 52.4% (176/336) with 92.05% (162/176) of patients in the ET group having one of three canonical driver mutations: JAK2 (52.0%), CALR (29.0%), and MPL (8.3%).